Abstract: Disclosed techniques include wound care image analysis using light signatures. A light wavelength is excited on a material sample. The exciting enables capture of fluorescence characteristics of the material sample. The material sample exhibits fluorescence characteristics along the Red-Green-Blue light wavelength spectrum. The material sample is illuminated with at least three additional light wavelengths. The illuminating enables capture of reflectance characteristics of the material sample. The material sample exhibits reflectance characteristics along the Red-Green-Blue light wavelength spectrum. An output indicative of biophysical status of the material sample is generated. The output is based on analysis of the fluorescence characteristics and the reflectance characteristics. The analysis includes identifying a wound topology within the material sample. The wound topology is identified based on measurements in the wound sample. A thermal image of the material sample is captured.

Abstract: Devices and systems for cell culture analysis are provided. A device for cell culture analysis includes a first component comprising a receptacle configured to receive a cell culture insert having an apical surface and a basal surface and a second component. The device further includes an inlet port disposed at at least one of the first and second components and an outlet port disposed at at least one of the first and second components. The first component and second component are releasably couplable and configured to define a flow path from the inlet port to the outlet port when in a coupled state. The flow path is at least partially defined by a surface of the second component, and the first component is configured to expose the basal surface of the cell culture insert to the flow path.

Abstract: Disclosed techniques include skin diagnostics using optical signatures. A plurality of optical excitation light wavelength bands is scanned on a material sample, wherein the material sample exhibits optical spectral characteristics along the light wavelength spectrum. Excitation response wavelengths emitted by the material sample are captured in response to the plurality of optical excitation light wavelength bands, wherein the capturing is accomplished using an imaging sensor. Output values of a plurality of pixels of an image from the imaging sensor are measured, wherein the image represents excitation response wavelengths captured by the imaging sensor, wherein the measuring detects optical spectral characteristics of the material sample, and wherein the optical spectral characteristics are in response to the plurality of optical excitation light wavelength bands.

Abstract: Disclosed techniques include exudate analysis using optical signatures. Access to a tissue exudate sample is obtained, wherein the tissue exudate sample contains one or more analytes representing a state of the tissue. The one or more analytes are isolated from the exudate sample on a substrate. The exudate is transferred from the substrate to an immunoassay. The immunoassay is illuminated with photons, wherein the illuminating comprises a controlled photon exposure. The controlled photon exposure comprises ambient lighting and/or one or more fluorescence excitation light wavelength bands. Light emanating from the immunoassay is imaged, wherein the imaging captures intensities of light wavelengths across the light wavelength spectrum. The imaging captures reflected light and fluorescent emanating light. A signature for the one or more analytes is generated, based on analysis of the intensities that were imaged. The signature expresses a magnitude for each of the one or more analytes.

Abstract: Provided herein are methods and compositions for the treatment of wounds in a mammalian subject. Particularly, novel bioactive polypeptides are provided that promote tissue repair and regeneration, including the activation of/stimulation of wound healing and wound closure, stimulate keratinocyte and endothelial cell motility and/or proliferation.

Abstract: Provided herein are methods and compositions for the treatment of wounds in a mammalian subject. Particularly, novel bioactive polypeptides are provided that promote tissue repair and regeneration, including the activation of/stimulation of wound healing and wound closure, stimulate keratinocyte and endothelial cell motility and/or proliferation.

Abstract: The present disclosure relates to protein and peptide chemistry. More particularly, it relates to compounds, compositions and uses thereof for promoting and inhibiting angiogenesis. The peptides of the present disclosure include peptides comprising SEQ ID NOs: 1-4 which promote angiogenesis and cell proliferation. Further, the anti-angiogenic compounds of the present disclosure include antisense oligonucleotides that hybridize or are complementary to the polynucleotides of SEQ ID NOs: 5-16, and the like.

Abstract: The present disclosure relates to protein and peptide chemistry. More particularly, it relates to compounds, compositions and uses thereof for promoting and inhibiting angiogenesis. The peptides of the present disclosure include peptides comprising SEQ ID NOs: 1-4 which promote angiogenesis and cell proliferation. Further, the anti-angiogenic compounds of the present disclosure include antisense oligonucleotides that hybridize or are complementary to the polynucleotides of SEQ ID NOs: 5-16, and the like.

Abstract: The present disclosure relates to protein and peptide chemistry. More particularly, it relates to compounds, compositions and uses thereof for promoting and inhibiting angiogenesis. The peptides of the present disclosure include peptides comprising SEQ ID NOs: 1-4 which promote angiogenesis and cell proliferation. Further, the anti-angiogenic compounds of the present disclosure include antisense oligonucleotides that hybridize or are complementary to the polynucleotides of SEQ ID NOs: 5-16, and the like.

Abstract: The present disclosure relates to protein and peptide chemistry. More particularly, it relates to compounds, compositions and uses thereof for promoting and inhibiting angiogenesis. The peptides of the present disclosure include peptides comprising SEQ ID NOs: 1-4 which promote angiogenesis and cell proliferation. Further, the anti-angiogenic compounds of the present disclosure include antisense oligonucleotides that hybridize or are complementary to the polynucleotides of SEQ ID NOs: 5-16, and the like.

Abstract: The present disclosure relates to protein and peptide chemistry. More particularly, it relates to compounds, compositions and uses thereof for promoting and inhibiting angiogenesis. The peptides of the present disclosure include peptides comprising SEQ ID NOs: 1-4 which promote angiogenesis and cell proliferation. Further, the anti-angiogenic compounds of the present disclosure include antisense oligonucleotides that hybridize or are complementary to the polynucleotides of SEQ ID NOs: 5-16, and the like.

Abstract: The present disclosure relates to protein and peptide chemistry. More particularly, it relates to compounds, compositions and uses thereof for promoting and inhibiting angiogenesis. The peptides of the present disclosure include peptides comprising SEQ ID NOs: 1-4 which promote angiogenesis and cell proliferation. Further, the anti-angiogenic compounds of the present disclosure include antisense oligonucleotides that hybridize or are complementary to the polynucleotides of SEQ ID NOs: 5-16, and the like.

Abstract: The current invention relates to methods and compositions for the treatment of wounds in a mammalian subject. Particularly, the invention relates to novel polypeptides and encoding nucleic acids that stimulate keratinocyte and endothelial cell motility and/or proliferation.

Abstract: The present disclosure relates to protein and peptide chemistry. More particularly, it relates to compounds, compositions and uses thereof for promoting and inhibiting angiogenesis. The peptides of the present disclosure include peptides comprising SEQ ID NOs: 1-4 which promote angiogenesis and cell proliferation. Further, the anti-angiogenic compounds of the present disclosure include antisense oligonucleotides that hybridize or are complementary to the polynucleotides of SEQ ID NOs: 5-16, and the like.

Abstract: The present disclosure relates to protein and peptide chemistry. More particularly, it relates to compounds, compositions and uses thereof for promoting and inhibiting angiogenesis. The peptides of the present disclosure include peptides comprising SEQ ID NOs: 1-4 which promote angiogenesis and cell proliferation. Further, the anti-angiogenic compounds of the present disclosure include antisense oligonucleotides that hybridize or are complementary to the polynucleotides of SEQ ID NOs: 5-16, and the like.

Abstract: Methods and compositions for the treatment of wounds in a mammalian subject are provided. Particularly, novel polypeptides and encoding nucleic acids that stimulate keratinocyte and endothelial cell motility and/or proliferation are provided.

Abstract: The present disclosure relates to protein and peptide chemistry. More particularly, it relates to compounds, compositions and uses thereof for promoting and inhibiting angiogenesis. The peptides of the present disclosure include peptides comprising SEQ ID NOs: 1-4 which promote angiogenesis and cell proliferation. Further, the anti-angiogenic compounds of the present disclosure include antisense oligonucleotides that hybridize or are complementary to the polynucleotides of SEQ ID NOs: 5-16, and the like.

Abstract: Methods and compositions for the treatment of wounds in a mammalian subject are provided. Particularly, novel polypeptides and encoding nucleic acids that stimulate keratinocyte and endothelial cell motility and/or proliferation are provided.

Abstract: The invention provides isolated nucleic acids molecules, designated HATF-1 and HRP-1 nucleic acid molecules, which are differentially expressed in hypertensive humans, rats, and mice. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing HATF-1 or HRP-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an HATF-1 or HRP-1 gene has been introduced or disrupted. The invention still further provides isolated HATF-1 and HRP-1 proteins, fusion proteins, antigenic peptides and anti-HATF-1 and anti-HRP-1 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

Abstract: The invention features a novel tumor-associated monoclonal antibody which recognizes the mitosis-associated antigen, 4F2. The invention provides methods and antibodies for identifying precancerous cells, mitotic cells, and displastic regions of tumors. The invention further provides methods, kits, and antibodies for inhibiting the proliferation of precancerous and/or endothelial cells, inhibiting tumor derived angiogenesis, inhibiting disorders associated with unwanted endothelial cell proliferation, and detecting the presence of tumor cells in a subject.